About Us


Argantrix is a new scientific research management consultancy formed in 2014.

Anglo-Indian Research Collaboration

We have extensive academic contacts in both countries in a range of scientific disciplines with whom we are working to establish joint and collaborative research projects.

Mr. Tom Sopwith

Image description

Managing Director - India


+91 9958 146 366

Chairman and Managing Director, Thomas Bio Creation India Pvt. Ltd. (BCi).


Business Development and Intellectual Property Director, SignMod Pharma Pvt Ltd, a company synthesizing complex, natural product-like macromolecules as drug candidates.

Former CEO and Business Development Director, Sarum Biosciences Ltd. Developing bacteriophages for targeted anti-bacterial therapeutic use.

Founder and a Founding Director of Imperial College Company Maker Ltd, formulating its strategy, writing its business plan and raising its first funding (£0.5 million).  It formed and grew 60 companies over a five year period 1997 to 2002 and became part of Imperial Innovations plc, floated in 2006 raising £55 million. Imperial Innovations has interests in over 100 companies and raised a further £140 million in November 2010 to invest in spin-out companies from Imperial, Oxford, Cambridge and University College London and now has a market capitalisation of over £300 million.

Prior to his commercial career he held a Research Fellowship at The National Heart and Lung Institute, University of London, in Respiratory Physiology and Medicine undertaking doctoral work in whole-body mapping (to give numerical analysis of thoraco-abdominal movement) and blood substitutes.


Dr. John Normanton

Image description

Managing Director - UK


+44 7831 800 683

Managing Director, Oxandia Ltd (UK) providing project management, company formation and strategic IP advice to companies and academia in the UK. (www.oxandia.co.uk)


He is also a Director of a number of other biotech companies including Lucilia Pharma Ltd. and CholesteniX Ltd.


Co-founder and former COO of Sterix Ltd., a pharmaceutical spin-out from Imperial College and the University of Bath in oncology and women's health which was acquired by the Ipsen Group in 2004.  During its life Sterix raised £8M in VC funding and signed major licences with pharmaceutical multinationals.  In addition, projects stemming from the Sterix portfolio have been involved in over 19 clinical trials and Sterix filed over 700 patent applications worldwide.


John has worked for the Ipsen Group, Sandoz (now part of Novartis), 3i plc and Imperial Innovations in a variety of areas including IP Management, Project Planning, Clinical Research and Technology Transfer.

Prior to this he held academic positions in neuro-physiology and neuropharmacology at the University of Oxford and Birmingham University conducting independent research into fundamental neuropeptide involvement in sleep.

John is a member of the UK Institute of Directors


Project Areas

Infectious Diseases

Infectious Diseases

The current global threat of antimicrobial resistance (AMR) is one of our prime focus areas.

We aim to harness the high-skill, low-cost advantages of Indian academia in conjunction with specialist skills and cutting edge research in UK universities to discover new therapeutic approaches to combat AMR.

Natural Plant Products

Natural Products

India is endowed with a wealth of untapped natural product resources, mainly of plant origin. 

We plan to use our unique access to Indian centres of excellence for ethnopharmacology & plant extract screening to identify suitable candidates for further preclinical assessment in the UK.

Laboratory Diagnostics


Accurate, rapid and reliable identification of disease is the cornerstone of clinical practice.

We are at the forefront of identifying new diagnostic technologies emerging from Indian universities and institutes and validating them through our unique collaborative links with major centres of excellence in the UK.